Switch theme
Sign up to access all valuation multiples
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
2013
87
LTM Revenue $33.1M
LTM EBITDA -$4.2M
$142M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioHarvest Sciences has a last 12-month revenue (LTM) of $33.1M and a last 12-month EBITDA of -$4.2M.
In the most recent fiscal year, BioHarvest Sciences achieved revenue of $25.2M and an EBITDA of -$6.9M.
BioHarvest Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioHarvest Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $33.1M | XXX | $25.2M | XXX | XXX | XXX |
| Gross Profit | $19.2M | XXX | $13.9M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | -$4.2M | XXX | -$6.9M | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -27% | XXX | XXX | XXX |
| EBIT | -$5.7M | XXX | -$7.0M | XXX | XXX | XXX |
| EBIT Margin | -17% | XXX | -28% | XXX | XXX | XXX |
| Net Profit | -$9.2M | XXX | -$12.9M | XXX | XXX | XXX |
| Net Margin | -28% | XXX | -51% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, BioHarvest Sciences's stock price is $7.
BioHarvest Sciences has current market cap of $128M, and EV of $142M.
See BioHarvest Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $142M | $128M | XXX | XXX | XXX | XXX | $-0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, BioHarvest Sciences has market cap of $128M and EV of $142M.
BioHarvest Sciences's trades at 5.6x EV/Revenue multiple, and -20.5x EV/EBITDA.
Equity research analysts estimate BioHarvest Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioHarvest Sciences has a P/E ratio of -14.0x.
See valuation multiples for BioHarvest Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $128M | XXX | $128M | XXX | XXX | XXX |
| EV (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBITDA | -33.6x | XXX | -20.5x | XXX | XXX | XXX |
| EV/EBIT | -25.1x | XXX | -20.3x | XXX | XXX | XXX |
| EV/Gross Profit | 7.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.0x | XXX | -9.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioHarvest Sciences's last 12 month revenue growth is 47%
BioHarvest Sciences's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
BioHarvest Sciences's rule of 40 is -30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioHarvest Sciences's rule of X is 105% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioHarvest Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 47% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -27% | XXX | XXX | XXX |
| EBITDA Growth | -132% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -30% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 105% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Agthia Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Acomo | XXX | XXX | XXX | XXX | XXX | XXX |
| ForFarmers | XXX | XXX | XXX | XXX | XXX | XXX |
| JDE Peets | XXX | XXX | XXX | XXX | XXX | XXX |
| Sligro Food Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioHarvest Sciences acquired XXX companies to date.
Last acquisition by BioHarvest Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . BioHarvest Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioHarvest Sciences founded? | BioHarvest Sciences was founded in 2013. |
| Where is BioHarvest Sciences headquartered? | BioHarvest Sciences is headquartered in United States of America. |
| How many employees does BioHarvest Sciences have? | As of today, BioHarvest Sciences has 87 employees. |
| Who is the CEO of BioHarvest Sciences? | BioHarvest Sciences's CEO is Mr. Ilan Sobel. |
| Is BioHarvest Sciences publicy listed? | Yes, BioHarvest Sciences is a public company listed on NAS. |
| What is the stock symbol of BioHarvest Sciences? | BioHarvest Sciences trades under BHST ticker. |
| When did BioHarvest Sciences go public? | BioHarvest Sciences went public in 2019. |
| Who are competitors of BioHarvest Sciences? | Similar companies to BioHarvest Sciences include e.g. Agthia Group, Acomo, ForFarmers, JDE Peets. |
| What is the current market cap of BioHarvest Sciences? | BioHarvest Sciences's current market cap is $128M |
| What is the current revenue of BioHarvest Sciences? | BioHarvest Sciences's last 12 months revenue is $33.1M. |
| What is the current revenue growth of BioHarvest Sciences? | BioHarvest Sciences revenue growth (NTM/LTM) is 47%. |
| What is the current EV/Revenue multiple of BioHarvest Sciences? | Current revenue multiple of BioHarvest Sciences is 4.3x. |
| Is BioHarvest Sciences profitable? | Yes, BioHarvest Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioHarvest Sciences? | BioHarvest Sciences's last 12 months EBITDA is -$4.2M. |
| What is BioHarvest Sciences's EBITDA margin? | BioHarvest Sciences's last 12 months EBITDA margin is -13%. |
| What is the current EV/EBITDA multiple of BioHarvest Sciences? | Current EBITDA multiple of BioHarvest Sciences is -33.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
